- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00238901
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)
The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems.
The objective of this trial is to assess the efficacy and safety of basiliximab, in combination with cyclosporin and MMF on the success rate of liver transplants for HCV related cirrhosis, in comparison with standard steroid treatment.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Patients undergoing first cadaver liver transplant Patients receiving an AB0 identical or compatible graft HCV+ patients (serology test within the last 12 months)
Exclusion Criteria Antiretroviral prophylactic treatment post-transplant Serological markers positive for Hepatitis B surface Antigen and Human Immunodeficiency Virus Recipients of a split liver transplant Other protocol-defined inclusion/exclusion criteria applied
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
12-month cumulative incidence of post-surgical graft loss and death
|
Secondary Outcome Measures
Outcome Measure |
---|
hepatitis C recurrence (see definition 3.5.2) at 6 and 12 months after transplant surgery.
|
treated and biopsy proven acute rejection at 6 and 12 months after transplant surgery.
|
graft survival and patient survival after treatment with either Simulect or steroids at 6 and 12 months.
|
viral load (HCV-RNA) after treatment with Simulect or steroids at Baseline, Month 1 and 3 post transplantation.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCHI621AIT06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedLiver Transplant | Kidney TransplantUnited States, Singapore
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Paragonix TechnologiesEnrolling by invitationLiver Diseases | Liver Transplant Disorder | Liver Dysfunction | Liver Transplant RejectionUnited States
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...CompletedLiver Transplant Recipient | Living Donor (of the Respective Liver Transplant Recipient)United States
Clinical Trials on Basiliximab
-
Drexel University College of MedicineNovartisTerminatedEnd Stage Renal DiseaseUnited States
-
McGill University Health Centre/Research Institute...Unknown
-
Asan Medical CenterUnknownKidney TransplantationKorea, Republic of
-
Fort Worth Clinical Sciences Working GroupTCU and UNTHSC School of MedicineNot yet recruitingSARS-CoV2 Infection | Cytokine Storm | SARS-CoV-2 Acute Respiratory Disease
-
Gary Archer Ph.D.National Cancer Institute (NCI)CompletedMalignant Neoplasms BrainUnited States
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; Soochow Hopes Hematonosis HospitalRecruitingSafety and EfficacyChina
-
University Health Network, TorontoNovartisCompletedEmphysema | COPD | Alpha-1 Antitrypsan DeficiencyCanada
-
Fuzhou General HospitalUnknownLiving-relative Kidney TransplantationChina
-
University Hospital, BrestUnknown
-
King Faisal Specialist Hospital & Research CenterRecruitingKidney TransplantationSaudi Arabia